Literature DB >> 20143250

The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Athina Kaprara1, Kalliopi Pazaitou-Panayiotou, Alexandros Kortsaris, Ekaterini Chatzaki.   

Abstract

Malignant tumors express multiple factors that have some role in the regulating networks supporting their ectopic growth. Recently, increased interest has been developing in the expression and biological role of the neuropeptides and receptors of the corticotropin releasing factor (CRF) system, the principal neuroendocrine mediator of the stress response, especially in the light of several R&D programs for small molecule antagonists that could present some anticancer therapeutic benefit. In the present article, we review the literature suggesting that the CRF system could be involved in the regulation of human cancer development. Potential implication in growth, metastasis, angiogenesis, or immune parameters via activation of locally expressed receptors could be clinically exploited by presenting targets of new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20143250     DOI: 10.1007/s00018-010-0265-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  108 in total

1.  Expression of corticotropin releasing hormone in malignant melanoma.

Authors:  Y Funasaka; H Sato; M Ichihashi
Journal:  Ann N Y Acad Sci       Date:  1999-10-20       Impact factor: 5.691

2.  Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3',5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase.

Authors:  C J Rossant; R D Pinnock; J Hughes; M D Hall; S McNulty
Journal:  Endocrinology       Date:  1999-04       Impact factor: 4.736

3.  Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases.

Authors:  Marko Radulovic; Cathrin Hippel; Joachim Spiess
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

4.  Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue.

Authors:  A Fjellestad-Paulsen; P A Abrahamsson; A Bjartell; M Grino; L Grimelius; H Hedeland; S Falkmer
Journal:  Acta Endocrinol (Copenh)       Date:  1988-12

5.  The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.

Authors:  Hossein Tezval; Steffanie Jurk; Farahnaz Atschekzei; Jürgen Serth; Markus A Kuczyk; Axel S Merseburger
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

6.  Influence of age on the clinical presentation of prolactinomas in male patients.

Authors:  E Delgrange; D Maiter; J Donckier; J Tourniaire
Journal:  Gerontology       Date:  1999 May-Jun       Impact factor: 5.140

7.  Urocortin 2 infusion in human heart failure.

Authors:  Mark E Davis; Christopher J Pemberton; Timothy G Yandle; Steve F Fisher; John G Lainchbury; Christopher M Frampton; Miriam T Rademaker; Mark Richards
Journal:  Eur Heart J       Date:  2007-08-25       Impact factor: 29.983

8.  Urocortin in human gastric mucosa: relationship to inflammatory activity.

Authors:  E Chatzaki; I Charalampopoulos; C Leontidis; I A Mouzas; M Tzardi; C Tsatsanis; A N Margioris; A Gravanis
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

9.  NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene.

Authors:  Katia P Karalis; Maria Venihaki; Jie Zhao; Lilian E van Vlerken; Christina Chandras
Journal:  J Biol Chem       Date:  2004-01-06       Impact factor: 5.157

10.  Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells.

Authors:  N Fazal; A Slominski; M A Choudhry; E T Wei; M M Sayeed
Journal:  FEBS Lett       Date:  1998-09-18       Impact factor: 4.124

View more
  9 in total

1.  Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Authors:  Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2015-06-19       Impact factor: 3.641

2.  The relationship between disease activity, quality of life, and personality types in rheumatoid arthritis and ankylosing spondylitis patients.

Authors:  T Donisan; V C Bojincă; M A Dobrin; D V Bălănescu; D Predețeanu; M Bojincă; F Berghea; D Opriș; L Groșeanu; A Borangiu; C L Constantinescu; R Ionescu; A R Bălănescu
Journal:  Clin Rheumatol       Date:  2017-04-27       Impact factor: 2.980

Review 3.  Key role of CRF in the skin stress response system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Desmond J Tobin; Theoharis C Theoharides; Jean Rivier
Journal:  Endocr Rev       Date:  2013-08-12       Impact factor: 19.871

4.  CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.

Authors:  Charalabos Pothoulakis; Monica Torre-Rojas; Marco A Duran-Padilla; Jonathan Gevorkian; Odysseas Zoras; Emmanuel Chrysos; George Chalkiadakis; Stavroula Baritaki
Journal:  Int J Cancer       Date:  2017-10-12       Impact factor: 7.316

5.  Immunolocalization of corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor.

Authors:  Naoko Sato; Kiyoshi Takagi; Takashi Suzuki; Yasuhiro Miki; Sota Tanaka; Satoru Nagase; Hitoshi Warita; Shin Fukudo; Fumiko Sato; Hironobu Sasano; Kiyoshi Ito
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

6.  Tumor Specific Epigenetic Silencing of Corticotropin Releasing Hormone -Binding Protein in Renal Cell Carcinoma: Association of Hypermethylation and Metastasis.

Authors:  Hossein Tezval; Natalia Dubrowinskaja; Inga Peters; Christel Reese; Katrin Serth; Faranaz Atschekzei; Jörg Hennenlotter; Arnulf Stenzl; Markus A Kuczyk; Jürgen Serth
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

7.  Involvement of CRF2 signaling in enterocyte differentiation.

Authors:  Benjamin Ducarouge; Marjolaine Pelissier-Rota; Rebecca Powell; Alain Buisson; Bruno Bonaz; Muriel Jacquier-Sarlin
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

8.  The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress.

Authors:  Alicia Arranz; Maria Venihaki; Berber Mol; Ariadne Androulidaki; Erini Dermitzaki; Olga Rassouli; Jorge Ripoll; Efstathios N Stathopoulos; Rosa P Gomariz; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2010-09-27       Impact factor: 27.401

9.  Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.

Authors:  Hossein Tezval; Faranaz Atschekzei; Inga Peters; Sandra Waalkes; Jörg Hennenlotter; Arnulf Stenzl; Jan U Becker; Axel S Merseburger; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Cancer       Date:  2013-04-22       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.